HC Wainwright Has Negative Outlook of TRVI FY2024 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI - Free Report) - Research analysts at HC Wainwright cut their FY2024 EPS estimates for Trevi Therapeutics in a note issued to investors on Wednesday, December 4th. HC Wainwright analyst O. Livnat now anticipates that the company will earn ($0.49) per share for the year, down from their prior forecast of ($0.47). HC Wainwright has a "Buy" rating on the stock. The consensus estimate for Trevi Therapeutics' current full-year earnings is ($0.49) per share. HC Wainwright also issued estimates for Trevi Therapeutics' Q1 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.40) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.49) EPS and FY2028 earnings at ($0.38) EPS.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). During the same period last year, the firm posted ($0.08) EPS.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partnrs upgraded shares of Trevi Therapeutics to a "strong-buy" rating in a report on Monday, September 9th. Needham & Company LLC reiterated a "buy" rating and set a $8.00 price target on shares of Trevi Therapeutics in a report on Wednesday, December 4th. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They set an "outperform" rating and a $7.00 price target on the stock. Raymond James began coverage on shares of Trevi Therapeutics in a report on Friday, August 30th. They set an "outperform" rating and a $9.00 price target on the stock. Finally, B. Riley restated a "buy" rating and set a $6.00 price objective on shares of Trevi Therapeutics in a research report on Monday, October 7th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $9.13.

Trevi Therapeutics Trading Down 3.6 %

TRVI traded down $0.10 during midday trading on Monday, reaching $2.66. The company's stock had a trading volume of 453,283 shares, compared to its average volume of 311,585. The firm has a market capitalization of $204.47 million, a price-to-earnings ratio of -6.05 and a beta of 0.96. Trevi Therapeutics has a 1 year low of $1.10 and a 1 year high of $4.00. The stock's 50-day moving average is $2.98 and its 200-day moving average is $2.91.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in TRVI. Vanguard Group Inc. raised its position in Trevi Therapeutics by 2.7% in the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company's stock worth $7,948,000 after acquiring an additional 60,249 shares during the period. Price T Rowe Associates Inc. MD bought a new position in Trevi Therapeutics in the first quarter worth approximately $47,000. Bank of New York Mellon Corp raised its position in Trevi Therapeutics by 38.8% in the second quarter. Bank of New York Mellon Corp now owns 178,511 shares of the company's stock worth $532,000 after acquiring an additional 49,884 shares during the period. Rhumbline Advisers raised its position in Trevi Therapeutics by 44.8% in the second quarter. Rhumbline Advisers now owns 75,218 shares of the company's stock worth $224,000 after acquiring an additional 23,263 shares during the period. Finally, American Century Companies Inc. raised its position in Trevi Therapeutics by 17.1% in the second quarter. American Century Companies Inc. now owns 54,108 shares of the company's stock worth $161,000 after acquiring an additional 7,902 shares during the period. 95.76% of the stock is currently owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.